The Wittrup Lab develops protein engineering technology and applies it to the discovery of new biopharmaceuticals. In particular, yeast surface display is used for the directed evolution of protein expression stability, affinity, and specificity.  A particular focus is on the development of anti-cancer drugs, with quantitative studies of cellular-level pharmacokinetics and pharmacodynamics.
Predict tumor uptake with our compartmental model.

Go to the (members only) Wittrup Lab wiki.

NEWS
K. Dane Wittrup elected to National Academy of Engineering >>more

Three Adimab antibodies enter human clinical trials >>more

K. Dane Wittrup elected a Fellow of the American Association for the Advancement of Science >>more
"Protein Engineering for Therapeutics A & B", vols. 502 & 503 of Methods in Enzymology, co-edited by K. Dane Wittrup and Greg Verdine, are published >>more